Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 202

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

The role of spironolactone in the treatment of patients with refractory hypertension

Open access
Ouzan, J., Perault, C., Lincoff, A. M., Carre, E., Mertes, M.·2002·American Journal of Hypertension

Abstract

BACKGROUND: Hypertension is resistant to pharmacologic therapy in 5% to 10% of patients. The current study tested whether addition of spironolactone to the treatment of patients with refractory hypertension would lead to adequate blood pressure (BP) control. METHODS: Among 520 patients who were referred for treatment of hypertension to one medical clinic from 1997 to 1999, a total of 25 patients who met the inclusion criteria of refractory hypertension were prospectively included in this study. The inclusion criteria were as follows: 1) hypertension of > or = 6 months without any apparent cause; 2) clinical BP measurement and mean 24-h ambulatory BP monitoring > 140/90 mm Hg despite treatment with at least two antihypertensive drugs; 3) no prior therapy with spironolactone; and 4) no renal insufficiency. Spironolactone was added to the previous regimen at a dosage of 1 mg/kg/day while any angiotensin converting enzyme inhibitor was suppressed. Serum potassium and creatinine levels were checked before the introduction of spironolactone and 1 month later. RESULTS: After 1 month of therapy with spironolactone, 23 patients had a clinical BP < 140/90 mm Hg. Ambulatory BP monitoring when compared before and 1 month after initiation of spironolactone decreased significantly (systolic BP from 152 +/- 2 mm Hg to 128 +/- 2 mm Hg, P < .001; and diastolic BP from 86 +/- 2 mm Hg to 76 +/- 2 mm Hg, P < .013). By 3 months after the introduction of spironolactone, the mean number of antihypertensive drugs required per patient was significantly reduced (from 3.2 +/- 0.2 to 2.1 +/- 0.2, P < .001). No patient required discontinuation of spironolactone due to adverse renal effects. CONCLUSION: Spironolactone is a safe, effective therapy for patients with refractory hypertension.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0895-7061(01)02342-1

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 202

Metadata

Authors
Ouzan, J., Perault, C., Lincoff, A. M., Carre, E., & Mertes, M.
Venue
American Journal of Hypertension
Published
2002-04-01
Volume
15
Issue
4
Pages
333-339
ISSN
  • 0895-7061 (ISSN-L)
  • 1941-7225
OpenAlex
W2039340766
Cited by
202
References
5
FWCI
4.98
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of spironolactone in the treatment of patients with refractory hypertension. https://app.cochat.ai/papers/10.1016/s0895-7061(01)02342-1
The paper
Ouzan, J., Perault, C., Lincoff, A. M., Carre, E., & Mertes, M. (2002). The role of spironolactone in the treatment of patients with refractory hypertension. American Journal of Hypertension. https://doi.org/10.1016/s0895-7061(01)02342-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.